Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
151 hedge funds and large institutions have $827M invested in Revance Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 37 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 41
20% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $9.78M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 37
4% less funds holding
Funds holding: 158 → 151 (-7)
44% less capital invested
Capital invested by funds: $1.48B → $827M (-$650M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$30.7M |
| 2 |
HM
HealthCor Management
New York
|
+$22.8M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$19.5M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$12.4M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$78.2M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$52.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$25.2M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$11.5M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$10.6M |
RVNC Hedge Fund Activity: Q4 2021 in Review
151 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2021, worth a combined $827M — down 44% from $1.48B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of RVNC and 34 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 56 added.
The largest buyer was JP Morgan Chase, adding an estimated $30.7M. The largest seller was ArrowMark Colorado Holdings, exiting entirely with an estimated $78.2M sold.
- 151 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2021, down from 158 in Q3 2021.
- Funds reported $827M of Revance Therapeutics, Inc. stock for Q4 2021, down 44% quarter-over-quarter.
- 34 funds opened new Revance Therapeutics, Inc. positions in Q4 2021 and 37 closed out, a net change of -3 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2021 was JP Morgan Chase, an estimated $30.7M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2021 was ArrowMark Colorado Holdings, an estimated $78.2M sold.
Based on aggregated 13F filings for Q4 2021.